Long-term clinical control in acromegaly patients with postoperative discordant nadir growth hormone during oral glucose tolerance test and insulin-like growth factor 1 levels: a retrospective observational study and literature review

What Was Tested

Researchers studied IGF-1 LR3 in this observational study publication.

Postoperative evaluation in patients with acromegaly typically involves measuring insulin-like growth factor 1 (IGF-1) levels and assessing growth hormone (GH) suppression via an oral glucose tolerance test (OGTT).

However, discrepancies between these results are not uncommon.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

The researchers retrospectively reviewed patients with acromegaly who underwent transsphenoidal resection of pituitary tumors at a single institution and had serial endocrinological evaluations for more than one year between May 2005 and July 2020.

Patients were divided into two groups: those with normal GH suppression during OGTT but elevated IGF-1 levels (Group I) and those with abnormal GH suppression but normal IGF-1 levels (Group II) at their 1-year postoperative evaluation.

How the Study Was Run

The researchers investigated whether IGF-1 levels normalized or re-elevated over time, alongside monitoring clinical signs and comorbidity management.

What Was Measured

Postoperative evaluation in patients with acromegaly typically involves measuring insulin-like growth factor 1 (IGF-1) levels and assessing growth hormone (GH) suppression via an oral glucose tolerance test (OGTT).

Despite this, there are very few studies examining long-term clinical outcomes in patients with persistent discordance between GH nadir and IGF-1 levels.

Topics PubMed links to this paper include Acromegaly, Insulin-Like Growth Factor I, Glucose Tolerance Test, Human Growth Hormone and Pituitary Neoplasms.

The authors tagged it with the keywords Discordant, GH, IGF-1, OGTT and Postoperative.

What This Means in Plain Language

This is an observational study of IGF-1 LR3.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Langenbeck's archives of surgery), a journal based in Germany.

More context: the IGF-1 LR3 compound page, all human trials.